title: ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
abstract: Targeting mTOR (mammalian target of rapamycin) is an effective approach in the treatment of advanced RCC (renal cell carcinoma). Rapamycin-like drugs (rapalogues) have shown clinical activities and have been approved for the treatment of RCC. Recently, with the development of ATP-competitive inhibitors of mTOR, therapies targeting mTOR have entered a new era. Here, we discuss the biological relevance of blocking mTOR in RCC and review the mechanisms of action of rapalogues in RCC. We also advance some perspectives on the use of ATP-competitive inhibitors of mTOR in RCC.
authors.affiliation: Department of Visceral Surgery, Service de Chirurgie Viscérale, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Pavillon 3, Av. de Beaumont, 1011 Lausanne, Switzerland.
authors.forename: Didier
authors.initials: D
authors.lastname: Roulin
authors.forename: Nicolas
authors.initials: N
authors.lastname: Demartines
authors.forename: Olivier
authors.initials: O
authors.lastname: Dormond
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D001667:Binding, Competitive / Q000502:physiology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D015507:Drugs, Investigational; D047428:Protein Kinase Inhibitors; D000255:Adenosine Triphosphate; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases